ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA

阿霉素是治疗恶性间皮瘤常用的化疗药物。Onconase是一种实验性药物（未经FDA批准），已显示出对恶性间皮瘤的活性。本研究的目的是确定Onconase入血治疗恶性间皮瘤是否优于注射阿霉素入血治疗。全国大约有160名患者将参加这项研究。这些患者将接受Onconase静脉输注，每周30分钟以上，或每3周一次阿霉素，最多6次。治疗将持续至少18周，或者直到肿瘤对治疗不再有反应。停止治疗后，医生将对患者进行监测，以确定后期副作用和未来的治疗。

Doxorubicin is a commonly used chemotherapy agent in the treatment of malignant mesothelioma. Onconase is an experimental (not approved by the FDA) drug that has shown activity against malignant mesothelioma. The purpose of this study is to determine whether Onconase, when administered into the blood stream, is better than injection of Doxorubicin into the blood stream for the treatment of malignant mesothelioma. Approximately 160 patients across the country will be enrolled on this study. These patients will receive either Onconase by intravenous infusion over 30 minutes weekly, or Doxorubicin every 3 weeks for a maximum of 6 doses. Treatment will continue for at least 18 weeks or until the tumor is no longer responding to treatment. After treatment has been stopped, patients will be monitored by a physician to determine late side effects and future therapy.